Liquidia rallies after judge rules against bid to delay Yutrepia

A federal judge dismissed United Therapeutics’ (UTHR) cross-claims against Liquidia (LQDA) and the Food and Drug Administration, allowing Liquidia’s Yutrepia to move forward for a launch as early as this month, Christopher Yasiejko and Nyah Phengsitthy of Bloomberg report. The ruling means Liquidia’s lung disease drug can receive final approval and launch when United ‘s exclusivity for the dry-powder-inhalation version of Tyvaso expires on May 23, according to Bloomberg. Shares of Liquidia are up 12%, or $1.72, to $15.70 in afternoon trading. Scotiabank called the ruling a “best case scenario” for Liquidia ahead of Yutrepia’s FDA action date on May 24.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.